TROPHIC DETERMINANTS OF OLIGODENDROCYTE DEVELOPMENT
Project Number5R01NS029648-03
Contact PI/Project LeaderGARD, ANTHONY LORENTZ
Awardee OrganizationUNIVERSITY OF SOUTH ALABAMA
Description
Abstract Text
Myelination of the CNS is an orderly process initiated by development of
the oligodendrocyte (OL). During an early proliferative phase, migratory
glial precursor cells seed axonal fiber tracts in brain as they enter a
specific lineage. Post-migratory differentiation heralds the end of
proliferation and the onset of programmed gene expression to construct the
myelin sheath. The regulation of these events is complex, involving the
interplay of factors intrinsic to the cell with environmental cues
encountered along its developmental course. The overall aim of this
project is to define specific environmental signals that direct
myelinogenesis at a crucial juncture of OL development, and resolve the
cellular and molecular mechanisms by which they operate. Investigation
will focus in vitro on the growth control of cells that have reached an
intermediate progenitor step of the lineage in vivo. In the rat these
cells are defined by a distinct surface antigenic phenotype; O4 antigen is
expressed in the absence of galactocerebroside, a marker for further
differentiation. Preliminary studies were designed to expose, in defined
cell culture, growth requirements of 04+GalC- as they form and proliferate
in vivo. Immunoselection technology was applied to isolate the progenitors
directly from premyelinating brain. It was shown that cells at this stage
are committed to terminal differentiation in vitro, but require extrinsic
signals for both survival and proliferation. Culture medium conditioned by
astrocytes from neonatal rat brain specifically prevents the death of
progenitor cultures, but is neither mitogenic nor inhibitory of their
subsequent differentiation program. Because the activity is potent,
proteinaceous (approximately 10-30 kDa), and distinct from tested mitogens
(bFGF and PDGF) it is hypothesized that OL viability is promoted by an
unrecognized trophic factor. Further experimentation in vitro will analyze
this factor with regard to its (a) cellular action (b) purification and
biochemical characterization (c) expression into adulthood and (d)
relationship to a genetic model of accelerated OL death in the
hypomyelinating jimpy mouse. Progenitor proliferation is restored normally
by neuron-conditioned culture medium, as well as basic fibroblast growth
factor (FGF) which at higher doses is mitogenic for "post-mitotic'. OL It
is hypothesized that FGF plays a changing role during the OL lineage,
with mitogenic as well as unrecognized functions. Further studies will
characterize FGF receptors and related signal transduction pathways
utilized by progenitors and differentiated oligodendrocytes. The capacity
to culture both cell types in isolation and high yield enables
pharmacological and biochemical analyses. These data are expected to
contribute to our knowledge of the epigenetic control of myelinogenesis and
will provide insight concerning a trophic basis for the etiology and
prospective treatment of dysmyelinating diseases.
National Institute of Neurological Disorders and Stroke
CFDA Code
DUNS Number
172750234
UEI
QB12VPNQQFE8
Project Start Date
30-September-1991
Project End Date
30-April-1996
Budget Start Date
01-May-1994
Budget End Date
30-April-1996
Project Funding Information for 1994
Total Funding
$134,366
Direct Costs
$92,432
Indirect Costs
$41,934
Year
Funding IC
FY Total Cost by IC
1994
National Institute of Neurological Disorders and Stroke
$134,366
Year
Funding IC
FY Total Cost by IC
Sub Projects
No Sub Projects information available for 5R01NS029648-03
Publications
Publications are associated with projects, but cannot be identified with any particular year of the project or fiscal year of funding. This is due to the continuous and cumulative nature of knowledge generation across the life of a project and the sometimes long and variable publishing timeline. Similarly, for multi-component projects, publications are associated with the parent core project and not with individual sub-projects.
No Publications available for 5R01NS029648-03
Patents
No Patents information available for 5R01NS029648-03
Outcomes
The Project Outcomes shown here are displayed verbatim as submitted by the Principal Investigator (PI) for this award. Any opinions, findings, and conclusions or recommendations expressed are those of the PI and do not necessarily reflect the views of the National Institutes of Health. NIH has not endorsed the content below.
No Outcomes available for 5R01NS029648-03
Clinical Studies
No Clinical Studies information available for 5R01NS029648-03
News and More
Related News Releases
No news release information available for 5R01NS029648-03
History
No Historical information available for 5R01NS029648-03
Similar Projects
No Similar Projects information available for 5R01NS029648-03